Free Access
Volume 21, Number 1-4, Janvier-Avril 2019
Page(s) 49 - 51
Section Éditorial / Editorial
Published online 14 October 2019
  • Park JS, Kim J, Elghiaty A, Ham WS (2018) Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 97:e12390 [CrossRef] [PubMed] [Google Scholar]
  • Feldman DR (2015) Update in germ cell tumors. Curr Opin Oncol 27:177–84 [PubMed] [Google Scholar]
  • Beyer J, Albers P, Altena R, et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the Third European Consensus Conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878–88 [CrossRef] [PubMed] [Google Scholar]
  • Selle F, Wittnebel S, Biron P, et al (2014) A phase II trial of highdose chemotherapy (HDCT) supported by hematopoietic stemcell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the multicentric TAXIF II study. Ann Oncol 25:1775–82 [CrossRef] [PubMed] [Google Scholar]
  • Chen R, Li H, Li Y, et al (2019) Loss of nuclear HOXA10 is associated with proliferation of testicular germ cell tumors. Cancer Research 79 (13 suppl; abstr 4646) [Google Scholar]
  • Singh R, Fazal Z, Bikorimana E, et al (2019) Epigenetic changes mediated by polycomb repressive complex 2 are associated with cisplatin-acquired resistance in testicular germ cell tumor. Proceedings of the American Association for Cancer Research, vol. 60, March, Poster 5188/6 [Google Scholar]
  • Nassar A, Agarwal A, Nagy R, et al (2019) Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors. J Clin Oncol 37 (suppl; abstr e16063) [Google Scholar]
  • Feldman DR, Hu JS, Patil S, et al (2019) Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). J Clin Oncol 37 (suppl; abstr 4563) [Google Scholar]
  • Feldman DR, Hu J, Dorff TB, et al (2016) Paclitaxel, ifosfamide, and cisplatin efficacy for first-line of patients with intermediateor poor-risk germ cell tumors. J Clin Oncol 34:2478–83 [CrossRef] [PubMed] [Google Scholar]
  • Abu Zaid MI, Milano MT, Dinh PC, et al (2019) Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG). J Clin Oncol 37 (suppl; abstr 11573) [Google Scholar]
  • Mego M, Svetlovska D, Chovanec M, et al (2019) Phase II study of avelumab in multiple relapsed/refractory testicular germ cell cancer. J Clin Oncol 37 (suppl; abstr e16045) [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.